From Interaction to Intervention: Intentional CYP Inhibition as a Scalable Strategy to Expand Access to High-Cost Therapies [0.03%]
从相互作用到干预：有意的CYP抑制作为扩大高成本药物获取范围的可扩展策略
Fernando De la Garza Salazar
Fernando De la Garza Salazar
Intentional cytochrome P450 (CYP) inhibition has been proposed as a pharmacoeconomic strategy capable of reducing oncology drug costs (33-90%) while maintaining clinical efficacy. While the pharmacokinetic effects of CYP inhibition have lon...
Beyond Algorithms: Machine Learning and Clinical Determinants of Voriconazole Plasma Levels in Therapeutic Drug Monitoring [0.03%]
超越算法：治疗药物监测中伏立康唑血药浓度的机器学习和临床决定因素分析
Ivan Maray,Claudia Orallo,Mateo Eiora-Osoro et al.
Ivan Maray et al.
Background and objective: Voriconazole is a broad-spectrum antifungal agent whose efficacy and toxicity are closely related to plasma concentrations, which are highly variable between individuals. Therapeutic drug monitor...
The Impact of Fluvoxamine on Clozapine and Norclozapine Serum Concentrations [0.03%]
氟伏沙明对氯氮平和脱氯氮平血药浓度的影响
G van Weringh,H J de Haas,L de Haan et al.
G van Weringh et al.
Background and objective: Fluvoxamine, a potent CYP1A2 inhibitor, increases clozapine serum concentrations by inhibiting its N-dealkylation to norclozapine, thus reducing norclozapine formation and increasing the clozapin...
Tacrolimus Pharmacokinetics in Pediatric Liver Transplant Recipients During the First Month After Transplantation [0.03%]
肝移植受者术后1个月的他克莫司药代动力学特征研究
Femke A Elzinga,Andrea R Hernandez-Hernandez,Hubert P J van der Doef et al.
Femke A Elzinga et al.
Introduction: Despite dosing protocols and tight therapeutic drug monitoring (TDM), tacrolimus concentrations remain highly variable in pediatric liver transplant (LTx) recipients during the first month post-transplantati...
Evaluation of Predictive Pharmacokinetic Models to Optimize Infliximab Therapy in Pediatric Inflammatory Bowel Disease [0.03%]
评估预测性药代动力学模型以优化抗肿瘤坏死因子药物英夫利昔单抗治疗儿科炎症性肠病的有效性
Paulo Caceres Guido,Guillermo Federico Taboada,Gisela Gruber et al.
Paulo Caceres Guido et al.
Background: The incidence of pediatric inflammatory bowel disease (IBD) rises yearly. Infliximab, a cornerstone of treatment, often has limited efficacy owing to high pharmacokinetic variability. Therapeutic drug monitori...
Bioavailability and Cellular Compatibility of a Novel Coenzyme Q10 Emulgel as an Alternative Oral Delivery System for Patients with Dysphagia: Preliminary Results from a Randomized Study [0.03%]
新型辅酶Q10乳胶凝胶的生物利用度和细胞相容性作为吞咽困难患者的口服递送系统的初步研究结果：随机对照试验报告
Ailin C Avila,Ezequiel Bernabeu,Diego Chiappetta et al.
Ailin C Avila et al.
Background: Coenzyme Q10 (CoQ10) plays a vital role in mitochondrial bioenergetics and functions as a potent endogenous antioxidant. Low CoQ10 levels have been associated with various neurodegenerative, metabolic, muscula...
Comment on "Assessing the Effect of Food on the Pharmacokinetics of Iclepertin in Healthy Volunteers: A Phase I, Open‑Label, Randomised, Cross‑Over Trial" [0.03%]
关于“评估食物对健康志愿者中Iclepertin药代动力学影响的Ⅰ期、开放标签、交叉重复试验”的评论
Abubakar Siddique,Own E Mohammad Najmi,Usman Ahmad
Abubakar Siddique
A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study Evaluating the Pharmacokinetics of Single-Dose Tapentadol Hydrochloride Intravenous Infusion and Tapentadol Hydrochloride Oral Tablets in Patients with Pain [0.03%]
一项多中心、随机、开放标签、阳性对照、平行组设计评价盐酸泰普森单次静脉滴注和盐酸 tapentadol 口服片在中国疼痛患者中的药代动力学研究
Zhiqin Hu,Tenghua Wang,Xiaoqiang Li et al.
Zhiqin Hu et al.
Background and objectives: Tapentadol is a novel, centrally acting, potent analgesic with a dual mechanism of action on µ-opioid receptors and noradrenaline reuptake in the central nervous system. This study was conducte...
Factors Affecting Pharmacokinetics of Sunitinib and Its Metabolite, SU12662: A Systematic Review of Population Pharmacokinetic Studies [0.03%]
影响舒尼替尼及其代谢产物SU12662药代动力学因素的系统评价：人群药代动力学研究
Heta N Shah,Jayashree Veerabhadrappa,Anagha Damre et al.
Heta N Shah et al.
Background and objective: Sunitinib malate is used to treat advanced renal cell carcinoma, gastrointestinal stromal, and pancreatic tumors. Wide variability in drug exposure is reported for both sunitinib and its active m...